Open original FDA record ↗Recall record
- FDA identifier
- Z-0461-2022
- Company in FDA record
- Abbott Molecular, Inc.
- FDA record creation date
- Jan 6, 2022
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
There is a software issue associated with the ability to properly complete a Field Service Engineer Maintenance and Diagnostics procedure.
Source facts
- Action
- On December 06, 2021 Abbott Molecular issued an attached Product Correction letter to all customers who received an Alinity m instrument (List Number 08N53 002). Customers are instructed to follow the Necessary Actions outlined in the Customer Letter until an Abbott Molecular representative assesses and/or corrects the board values on the Alinity m System. Abbott personnel will follow up with customers by e mailing and or follow up visits/phone calls.
- Initiated
- 2021-12-06
- Root cause
- Software design
- Distribution
- Worldwide distribution - US Nationwide and the countries of Australia, Austria, Belgium, Brazil, Cambodia, Canada, Chile, Colombia, Czech Republic, Egypt, El Salvador, Estonia, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Malawi, Malaysia, Mexico, Montenegro, Morocco, Mozambique, Netherlands, New Zealand, Norway, Pakistan, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Uganda, United Kingdom, and Vietnam.
- Recall number
- Z-0461-2022
- Recall status
- Open, Classified
- CDRH record ID
- 190679
- FDA record created
- 2022-01-06
- Recall event number
- 89167